[CAS NO. 5289-74-7] Crustecdysone
PRODUCTS SPECIFICATIONS [5289-74-7]
DESCRIPTION [5289-74-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 480.63 |
| Molecular Formula | C27H44O7 |
| SMILES | O[C@@H]1[C@H](O)C[C@](C(C=C2[C@]3([H])CC[C@@]4(C)[C@@]2(O)CC[C@]4([H])[C@](O)(C)[C@H](O)CCC(O)(C)C)=O)([H])[C@]3(C)C1 |
1 Publications Citing Use of MCE
Summary
Crustecdysone (20-Hydroxyecdysone) is a naturally occurring ecdysteroid hormone isolated from Serratula coronata which controls the ecdysis (moulting) and metamorphosis of arthropods, it inhibits caspase activity and induces autophagy via the 20E nuclear receptor complex, EcR-USP [1] . Crustecdysone exhibits regulatory or protective roles in the cardiovascular system [2] . Crustecdysone is an active metabolite of Ecdysone (HY-N0179) [3] .
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
Crustecdysone induces cell autophagy and caspase-3 activity in the remodeling fat body of Drosophila [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Crustecdysone (5 or 10 mg/kg; i.p., once daily, for 6 weeks) reduces blood pressure and prevents dilated cardiac hypertrophy in SHR rats [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male spontaneous hypertensive (SHR) rats [2] |
| Dosage: | 5 or 10 mg/kg |
| Administration: | Intraperitoneal injection; 5 or 10 mg/kg , once daily, for 6 weeks |
| Result: | Decreased seminal vesicular weight, systolic pressure, and left ventricular dilatation caused by hypertension. Increased testicular weight and amount of β-isoform. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04827537 | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan |
Giardia Lamblia Infection
|
January 1, 2021 | Phase 2|Phase 3 |
Appearance
Solid
Source
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL ( 208.06 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0806 mL | 10.4030 mL | 20.8060 mL |
| 5 mM | 0.4161 mL | 2.0806 mL | 4.1612 mL |
| 10 mM | 0.2081 mL | 1.0403 mL | 2.0806 mL |
References
- [1] Liu H, et al. E93 predominantly transduces 20-hydroxyecdysone signaling to induce autophagy and caspase activity in Drosophila fat body. Insect Biochem Mol Biol. 2014 Feb;45:30-9.
- [2] Phungphong S, et al. 20-Hydroxyecdysone attenuates cardiac remodeling in spontaneously hypertensive rats. Steroids. 2017 Oct;126:79-84.
- [3] Minglei Lu, et al. Ecdysone Elicits Chronic Renal Impairment via Mineralocorticoid-Like Pathogenic Activities. Cell Physiol Biochem. 2018;49(4):1633-1645.
Synonyms